BCRX
Biocryst Pharmaceuticals Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Biocryst Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.55%
vs ±10.0% implied · ×0.05
shaded = implied · ▲▼ = realized
Biocryst Pharmaceuticals Inc
8.46
No thesis.
Largest filed tie
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BlackRockBlackRockindex-like | $238.9M | 9.06% | +5.48% | |
| 2 | RA Capital ManagementRA Capital Management | $158.3M | 6.00% | 0.00% | |
| 3 | State StreetState Streetindex-like | $151.9M | 5.76% | +24.43% | |
| 4 | Deerfield ManagementDeerfield | $151.0M | 5.72% | +0.39% | |
| 5 | Vanguard Capital ManagementVanguardindex-like | $113.6M | 4.31% | +2.05% | |
| 6 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $111.4M | 4.22% | −0.94% | |
| 7 | TCG Crossover ManagementTCG Crossover | $110.2M | 4.18% | 0.00% | |
| 8 | Perceptive AdvisorsPerceptive | $103.1M | 3.91% | +38.67% | |
| 9 | Jupiter TopcoJupiter Topco | $95.3M | 3.61% | — | |
| 10 | Vestal Point CapitalVestal Point Capital | $83.0M | 3.15% | +18.15% | |
| 11 | Two Sigma InvestmentsTwo Sigma | $67.8M | 2.57% | +5.99% | |
| 12 | Geode Capital ManagementGeodeindex-like | $62.5M | 2.37% | +8.05% | |
| 13 | Standard Life AberdeenStandard Life Aberdeen | $53.1M | 2.01% | +5.36% | |
| 14 | UBS GroupUBS | $50.8M | 1.92% | +2.72% | |
| 15 | Bank of AmericaBank of America | $48.0M | 1.82% | −5.70% | |
| 16 | Goldman Sachs GroupGoldman Sachs | $44.8M | 1.70% | +90.93% | |
| 17 | Frazier Life Sciences ManagementFrazier Life Sciences | $40.1M | 1.52% | 0.00% | |
| 18 | NuveenNuveenindex-like | $40.1M | 1.52% | +4.92% | |
| 19 | Jane Street GroupJane Street | $38.2M | 1.45% | +211.97% | |
| 20 | Millennium ManagementMillennium | $33.9M | 1.29% | +968.46% | |
| 21 | GW&K Investment ManagementGW&K | $31.7M | 1.20% | −2.14% | |
| 22 | Dimensional Fund AdvisorsDimensional | $27.2M | 1.03% | +1.05% | |
| 23 | Fisher Asset ManagementFisher | $26.0M | 0.99% | −4.73% | |
| 24 | Renaissance TechnologiesRenaissance Technologies | $25.3M | 0.96% | +225.65% | |
| 25 | Kynam Capital ManagementKynam | $25.2M | 0.96% | −55.59% |
318 managers report $2.6B of Biocryst Pharmaceuticals on form 13F for the quarter ended Jun 30 '26. 34 of them hold 80% of it; BlackRock is largest at 9.06%.
Expected move
Inputsspot 8.47exp Nov 20ATM strike 8ATM straddle 1.00IV 58%